Urofollitropin

Pharmaceutical drug
  • G03GA04 (WHO)
Legal statusLegal status
  • US: ℞-only
IdentifiersCAS Number
  • 97048-13-0 checkY
PubChem CID
  • 62819
IUPHAR/BPS
  • 1157
DrugBank
  • DB00094 ☒N
ChemSpider
  • none
UNII
  • W9BB98U6HP
KEGG
  • D06400 checkY
ChEMBL
  • ChEMBL1201520 ☒N
ECHA InfoCard100.212.030 Edit this at WikidataChemical and physical dataFormulaC975H1513N267O304S26Molar mass22672.95 g·mol−1 ☒NcheckY (what is this?)  (verify)

Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified[1] to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility.[2] It is also used with in vitro fertilization methods. The dosage is adjusted to each individual's response.[2]

The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment.[2]

Bravelle sold in the United States from March 2014 through October 2015 is subject to a recall and refund by its maker, Ferring Pharmaceuticals, because certain batches of the medicine had a lower strength than stated.[3]

References

  1. ^ van Wely M, Yding Andersen C, Bayram N, van der Veen F (2005). "Urofollitropin and ovulation induction". Treatments in Endocrinology. 4 (3): 155–65. doi:10.2165/00024677-200504030-00004. PMID 15898821. S2CID 26069210.
  2. ^ a b c Drugs.com: Urofollitropin (Intramuscular route, Subcutaneous route, Injection route)
  3. ^ Enforcement Report - Week of October 21, 2015, Food and Drug Administration

External links

  • Bravelle, by Ferring Pharmaceuticals, Switzerland
  • Fostimon by Institut Biochemique SA, Switzerland
  • v
  • t
  • e
Merck & Co., Inc.
Corporate directors
SubsidiariesProducts
Schering-Plough
FacilitiesPublications
  • v
  • t
  • e
GnRHTooltip Gonadotropin-releasing hormone and gonadotropins
GnRH modulators
(incl. analogues)
Agonists
Antagonists
Gonadotropins
Preparations
Others
(indirect)
Progonadotropins
Antigonadotropins
See also
GnRH and gonadotropin receptor modulators
Androgens and antiandrogens
Estrogens and antiestrogens
Progestogens and antiprogestogens
  • v
  • t
  • e
GnRHTooltip Gonadotropin-releasing hormone receptor and gonadotropin receptor modulators
GnRHTooltip Gonadotropin-releasing hormone receptor
Gonadotropin
LH/hCGTooltip Luteinizing hormone/choriogonadotropin receptor
FSHTooltip Follicle-stimulating hormone receptor
  • NAMs: Non-peptides: ADX-61623